Passage Bio Inc (PASG)

(10% Negative) PASSAGE BIO, INC. (PASG) Announces Delay in patients Trials for GM1 gangliosidosis (GM1) Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment